{"filing":{"accession_number":"0001193125-26-391378","cik":"0001835022","ticker":"COYA","company_name":"Coya Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"d896544d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526391378/d896544d8k.htm"},"events":[{"id":33495,"run_id":30797,"accession_number":"0001193125-26-391378","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Coya Therapeutics announced enrollment of the 100th patient in its Phase 2/3 ALSTARS Trial for COYA 302 in ALS treatment, with anticipated topline data in early Q2 2027. This is a material clinical development milestone for a biopharmaceutical company with a lead product candidate, affecting investor assessment of pipeline progress and regulatory pathway advancement. While not fitting a specific named event type, this is clearly an operational/strategic milestone disclosure.","company_name":"Coya Therapeutics, Inc.","ticker":"COYA","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36953,"accession_number":"0001193125-26-391378","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Coya Therapeutics announced enrollment of the 100th patient in its Phase 2/3 ALSTARS Trial for COYA 302 in ALS treatment, with anticipated topline data in early Q2 2027. This is a material clinical development milestone for a biopharmaceutical company with a lead product candidate, affecting investor assessment of pipeline progress and regulatory pathway advancement. While not fitting a specific named event type, this is clearly an operational/strategic milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:16:48.465669+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36953,"accession_number":"0001193125-26-391378","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Coya Therapeutics announced enrollment of the 100th patient in its Phase 2/3 ALSTARS Trial for COYA 302 in ALS treatment, with anticipated topline data in early Q2 2027. This is a material clinical development milestone for a biopharmaceutical company with a lead product candidate, affecting investor assessment of pipeline progress and regulatory pathway advancement. While not fitting a specific named event type, this is clearly an operational/strategic milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:16:48.465669+00:00","company_name":"Coya Therapeutics, Inc.","ticker":"COYA","filing_date":"2026-09-15"}]}